Larisa Y Poluektova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1120060/publications.pdf

Version: 2024-02-01

106 papers 4,035 citations

38 h-index 59 g-index

109 all docs 109 docs citations

109 times ranked 4961 citing authors

#	Article	IF	CITATIONS
1	Ethanol attenuates presentation of cytotoxic Tâ€lymphocyte epitopes on hepatocytes of HBVâ€infected humanized mice. Alcoholism: Clinical and Experimental Research, 2022, 46, 40-51.	1.4	4
2	Alcohol basic and translational research 15th Charles Lieber - 1st Samuel French satellite symposium. Experimental and Molecular Pathology, 2022, , 104750.	0.9	4
3	Alcohol and HIV-Derived Hepatocyte Apoptotic Bodies Induce Hepatic Stellate Cell Activation. Biology, 2022, 11, 1059.	1.3	4
4	Alcohol-and-HIV-Induced Lysosomal Dysfunction Regulates Extracellular Vesicles Secretion in Vitro and in Liver-Humanized Mice. Biology, 2021, 10, 29.	1.3	13
5	Pancreatogenic Diabetes: Triggering Effects of Alcohol and HIV. Biology, 2021, 10, 108.	1.3	8
6	Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology, 2021, 18, 13.	0.9	20
7	Recovery of Latent HIV-1 from Brain Tissue by Adoptive Cell Transfer in Virally Suppressed Humanized Mice. Journal of NeuroImmune Pharmacology, 2021, 16, 796-805.	2.1	7
8	Alcohol-Induced Lysosomal Damage and Suppression of Lysosome Biogenesis Contribute to Hepatotoxicity in HIV-Exposed Liver Cells. Biomolecules, 2021, 11, 1497.	1.8	10
9	CD4+ effector T cells accelerate Alzheimer's disease in mice. Journal of Neuroinflammation, 2021, 18, 272.	3.1	48
10	miRâ€15aâ€5p, miRâ€15bâ€5p, and miRâ€16â€5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Molecular Oncology, 2020, 14, 180-196.	2.1	91
11	Acetaldehyde suppresses HBV-MHC class I complex presentation on hepatocytes via induction of ER stress and Golgi fragmentation. American Journal of Physiology - Renal Physiology, 2020, 319, G432-G442.	1.6	9
12	Genetically modified mouse models to help fight COVID-19. Nature Protocols, 2020, 15, 3777-3787.	5.5	26
13	Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Current HIV Research, 2020, 18, 19-28.	0.2	9
14	HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice. Scientific Reports, 2020, 10, 9746.	1.6	5
15	Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 38.	1.8	7
16	A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102185.	1.7	12
17	Role of alcohol in pathogenesis of hepatitis B virus infection. World Journal of Gastroenterology, 2020, 26, 883-903.	1.4	24
18	Obeticholic acid attenuates human immunodeficiency virus/alcohol metabolism-induced pro-fibrotic activation in liver cells. World Journal of Hepatology, 2020, 12, 965-975.	0.8	4

#	Article	IF	CITATIONS
19	Eluted 25-hydroxyvitamin D3 from radially aligned nanofiber scaffolds enhances cathelicidin production while reducing inflammatory response in human immune system-engrafted mice. Acta Biomaterialia, 2019, 97, 187-199.	4.1	20
20	Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nature Communications, 2019, 10, 2753.	5.8	222
21	Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis. Journal of Visualized Experiments, 2019, , .	0.2	4
22	Human-like NSG mouse glycoproteins sialylation pattern changes the phenotype of human lymphocytes and sensitivity to HIV-1 infection. BMC Immunology, 2019, 20, 2.	0.9	8
23	Acetaldehyde suppresses the display of HBV-MHC class I complexes on HBV-expressing hepatocytes. American Journal of Physiology - Renal Physiology, 2019, 317, G127-G140.	1.6	21
24	Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL. Antiviral Research, 2019, 168, 134-145.	1.9	5
25	Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World Journal of Gastroenterology, 2019, 25, 398-410.	1.4	42
26	Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. Molecular Neurodegeneration, 2019, 14, 12.	4.4	53
27	Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Frontiers in Immunology, 2019, 10, 340.	2.2	20
28	Alcohol Metabolism Potentiates HIV-Induced Hepatotoxicity: Contribution to End-Stage Liver Disease. Biomolecules, 2019, 9, 851.	1.8	25
29	Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 272-280.	1.3	9
30	Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Journal of NeuroVirology, 2018, 24, 398-410.	1.0	11
31	Creation of a long-acting nanoformulated dolutegravir. Nature Communications, 2018, 9, 443.	5.8	101
32	Human hepatocytes depletion in the presence of HIV-1 infection in dual reconstituted humanized mice. Biology Open, 2018, 7, .	0.6	18
33	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials, 2018, 151, 53-65.	5.7	77
34	Liver as a target of human immunodeficiency virus infection. World Journal of Gastroenterology, 2018, 24, 4728-4737.	1.4	45
35	Hepatitis C Virus-Infected Apoptotic Hepatocytes Program Macrophages and Hepatic Stellate Cells for Liver Inflammation and Fibrosis Development: Role of Ethanol as a Second Hit. Biomolecules, 2018, 8, 113.	1.8	14
36	Human Lymphocyte Biology and Its Application to Humanized Mice. , 2017, , 201-216.		0

#	Article	IF	Citations
37	A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology, 2017, 14, 17.	0.9	94
38	Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection. Scientific Reports, 2017, 7, 9578.	1.6	17
39	Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. DMM Disease Models and Mechanisms, 2017, 10, 1489-1502.	1.2	15
40	Neuropharmacologic Approaches to Restore the Brain's Microenvironment. Journal of NeuroImmune Pharmacology, 2016, 11, 484-494.	2.1	10
41	Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts―2015 Workshop Summary. AIDS Research and Human Retroviruses, 2016, 32, 109-119.	0.5	57
42	Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice. Scientific Reports, 2016, 6, 26876.	1.6	47
43	HIV-1 cellular and tissue replication patterns in infected humanized mice. Scientific Reports, 2016, 6, 23513.	1.6	59
44	Acetaldehyde Disrupts Interferon Alpha Signaling in Hepatitis C Virusâ€Infected Liver Cells by Upâ€Regulating <scp>USP</scp> 18. Alcoholism: Clinical and Experimental Research, 2016, 40, 2329-2338.	1.4	38
45	Simple and reliable genotyping protocol for mouse PrkdcSCID mutation. Journal of Immunological Methods, 2016, 431, 60-62.	0.6	1
46	The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 109-122.	1.7	27
47	Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Molecular Neurobiology, 2016, 53, 3286-3297.	1.9	14
48	FAT10 suppression stabilizes oxidized proteins in liver cells: Effects of HCV and ethanol. Experimental and Molecular Pathology, 2015, 99, 506-516.	0.9	13
49	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	5 . 7	58
50	Amphiphilic Cationic Nanogels as Brain-Targeted Carriers for Activated Nucleoside Reverse Transcriptase Inhibitors. Journal of NeuroImmune Pharmacology, 2015, 10, 88-101.	2.1	22
51	Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Research, 2015, 120, 85-88.	1.9	23
52	Influence of age, irradiation and humanization on NSG mouse phenotypes. Biology Open, 2015, 4, 1243-1252.	0.6	24
53	Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics. Biomaterials, 2015, 70, 37-47.	5.7	27
54	Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Molecular Neurodegeneration, 2014, 9, 58.	4.4	52

#	Article	IF	Citations
55	Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. Aids, 2014, 28, 2201-2211.	1.0	4
56	Human Hepatocytes and Hematolymphoid Dual Reconstitution in Treosulfan-Conditioned uPA-NOG Mice. American Journal of Pathology, 2014, 184, 101-109.	1.9	56
57	Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 177-185.	1.7	49
58	Ethanol affects hepatitis C pathogenesis: Humanized SCID Alb-uPA mouse model. Biochemical and Biophysical Research Communications, 2014, 450, 773-776.	1.0	9
59	Brain HIV-1 Infection Modeling in Humanized Mice. , 2014, , 305-312.		2
60	Humanized Mice. Springer Protocols, 2014, , 483-495.	0.1	0
61	Improved Visualization of Neuronal Injury Following Glial Activation by Manganese Enhanced MRI. Journal of NeuroImmune Pharmacology, 2013, 8, 1027-1036.	2.1	13
62	Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1224-1238.	2.1	30
63	Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection. Biomaterials, 2013, 34, 3846-3857.	5.7	31
64	Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. Aids, 2012, 26, 2135-2144.	1.0	121
65	Rodent models for HIV-associated neurocognitive disorders. Trends in Neurosciences, 2012, 35, 197-208.	4.2	66
66	Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. International Journal of Nanomedicine, 2012, 7, 2373.	3.3	48
67	Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice. International Journal of Nanomedicine, 2012, 7, 2557.	3.3	51
68	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1â€"Infected Human Peripheral Blood Lymphocyteâ€"Reconstituted Mice. Journal of Infectious Diseases, 2012, 206, 1577-1588.	1.9	62
69	Can Humanized Mice Reflect the Complex Pathobiology of HIV-Associated Neurocognitive Disorders?. Journal of NeuroImmune Pharmacology, 2012, 7, 352-362.	2.1	27
70	IL-23 in Infections, Inflammation, Autoimmunity and Cancer: Possible Role in HIV-1 and AIDS. Journal of NeuroImmune Pharmacology, 2012, 7, 95-112.	2.1	29
71	Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice. Journal of Neuroscience, 2011, 31, 3148-3157.	1.7	110
72	Murine Models for NeuroAIDS. , 2011, , 414-430.		1

#	Article	lF	Citations
73	Adaptive Immunity., 2011, , 131-145.		O
74	Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS. Journal of NeuroImmune Pharmacology, 2010, 5, 456-468.	2.1	48
75	CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice. Journal of Immunology, 2010, 184, 7082-7091.	0.4	80
76	Neuroprotective Activities of CEP-1347 in Models of NeuroAIDS. Journal of Immunology, 2010, 184, 746-756.	0.4	47
77	Nano-NRTIs: Efficient Inhibitors of HIV Type-1 in Macrophages with a Reduced Mitochondrial Toxicity. Antiviral Chemistry and Chemotherapy, 2010, 21, 1-14.	0.3	47
78	Links between Progressive HIV-1 Infection of Humanized Mice and Viral Neuropathogenesis. American Journal of Pathology, 2010, 177, 2938-2949.	1.9	94
79	Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of Neuroimmunology, 2009, 213, 47-59.	1.1	24
80	Modulation of innate immunity by copolymerâ€1 leads to neuroprotection in murine HIVâ€1 encephalitis. Glia, 2008, 56, 223-232.	2.5	18
81	Lymphocytes and the Nervous System. , 2008, , 135-149.		0
82	Copolymer-1 Induces Adaptive Immune Anti-inflammatory Glial and Neuroprotective Responses in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2007, 179, 4345-4356.	0.4	36
83	Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2 â^'/â^' γ c â^'/â^' Mice. Journal of Virology, 2007, 81, 2700-2712.	1.5	130
84	Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, 2827-2835.	0.6	241
85	Immune privilege and HIV-1 persistence in the CNS. Immunological Reviews, 2006, 213, 180-194.	2.8	57
86	Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase. Toxicology and Applied Pharmacology, 2006, 214, 152-165.	1.3	14
87	Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. Journal of Leukocyte Biology, 2006, 80, 1165-1174.	1.5	64
88	Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood, 2005, 106, 2382-2390.	0.6	144
89	Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Clia, 2005, 52, 344-353.	2.5	54
90	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	1.5	44

#	Article	IF	CITATIONS
91	Neuroprotective Mechanisms of Lithium in Murine Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2005, 25, 8375-8385.	1.7	72
92	Advances in Neuroimaging for HIV-1 Associated Neurological Dysfunction: Clues to the Diagnosis, Pathogenesis and Therapeutic Monitoring. Current HIV Research, 2004, 2, 61-78.	0.2	36
93	Neuroregulatory Events Follow Adaptive Immune-Mediated Elimination of HIV-1-Infected Macrophages: Studies in a Murine Model of Viral Encephalitis. Journal of Immunology, 2004, 172, 7610-7617.	0.4	51
94	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.0	20
95	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.0	3
96	OTK18 expression in brain mononuclear phagocytes parallels the severity of HIV-1 encephalitis. Journal of Neuroimmunology, 2004, 150, 186-198.	1.1	19
97	Levels of human immunodeficiency virus type 1 (HIV-1) replication in macrophages determines the severity of murine HIV-1 encephalitis. Journal of NeuroVirology, 2004, 10, 82-90.	1.0	23
98	Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. Journal of Neuroscience Research, 2003, 73, 284-295.	1.3	87
99	Neuroprotective Activities of Sodium Valproate in a Murine Model of Human Immunodeficiency Virus-1 Encephalitis. Journal of Neuroscience, 2003, 23, 9162-9170.	1.7	113
100	Generation of Cytotoxic T Cells Against Virus-Infected Human Brain Macrophages in a Murine Model of HIV-1 Encephalitis. Journal of Immunology, 2002, 168, 3941-3949.	0.4	69
101	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. Journal of Neuroimmunology, 2001, 120, 112-128.	1.1	43
102	Immunoregulatory effects of N9-benzyl- and N7-benzyl-8-bromoguanines. International Journal of Immunopharmacology, 1999, 21, 777-792.	1.1	0
103	Involvement of protein kinase A in histamine-mediated inhibition of IL-2 mRNA expression in mouse splenocytes. Immunopharmacology, 1999, 41, 77-87.	2.0	22
104	Protein kinase A inhibitors reverse histamine-mediated regulation of IL-5 secretion. Immunopharmacology, 1998, 39, 9-19.	2.0	23
105	In vitro lymphotoxicity and selective t cell immunotoxicity of high doses of acyclovir and its derivatives in mice. International Journal of Immunopharmacology, 1996, 18, 429-438.	1.1	2
106	Immunostimulating properties of the complexes of inosine derivatives. International Journal of Immunopharmacology, 1995, 17, 941-947.	1.1	2